Chenming Bs Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chenming Bs Yu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Dandan Zhou
Department of Radiology, The First Hospital of Jilin University, Changchun, China
1 shared publication Jiali Me Zhang
School of Life Science and Technology, China Pharmaceutical University, Nanjing, China; and
1 shared publicationShuai Dsc Jiang
School of Life Science and Technology, China Pharmaceutical University, Nanjing, China; and
1 shared publicationWenhui Bs Jia
School of Life Science and Technology, China Pharmaceutical University, Nanjing, China; and
1 shared publication- Xiangyu Liu
Department of Radiology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China
1 shared publication - Xin Chen
Department of Radiology, The First Hospital of Jilin University, Changchun, China
1 shared publication
Latest Publications
- 1 July 2024
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 84 (1) , 71-80
Dual Inhibition of Factor XIIa and Factor XIa Produces a Synergistic Anticoagulant Effect
Clinical practice shows that a critical unmet need in the field of thrombosis prevention is the availability of anticoagulant therapy without bleeding risk. Inhibitors against FXIa or FXIIa have been extensively studied because of their low bleeding risk. However, whether these compounds produce synergistic effects has not yet been explored. In this study, analyses of activated partial thromboplastin time in combination with the FXIa inhibitor PN2KPI and the FXIIa inhibitor Infestin4 at different proportions were performed using the SynergyFinder tool identifying synergistic anticoagulation effects. Both an FeCl3-induced carotid artery thrombosis mouse model and a transient occlusion of the middle cerebral artery mouse model showed that the combination of PN2KPI and Infestin4, which are 28.57% and 6.25% of the effective dose, respectively, significantly prevents coagulation, and furthermore, dual inhibition does not cause bleeding risk.
- 1 July 2024
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 84 (1) , 71-80
Dual Inhibition of Factor XIIa and Factor XIa Produces a Synergistic Anticoagulant Effect
Clinical practice shows that a critical unmet need in the field of thrombosis prevention is the availability of anticoagulant therapy without bleeding risk. Inhibitors against FXIa or FXIIa have been extensively studied because of their low bleeding risk. However, whether these compounds produce synergistic effects has not yet been explored. In this study, analyses of activated partial thromboplastin time in combination with the FXIa inhibitor PN2KPI and the FXIIa inhibitor Infestin4 at different proportions were performed using the SynergyFinder tool identifying synergistic anticoagulation effects. Both an FeCl3-induced carotid artery thrombosis mouse model and a transient occlusion of the middle cerebral artery mouse model showed that the combination of PN2KPI and Infestin4, which are 28.57% and 6.25% of the effective dose, respectively, significantly prevents coagulation, and furthermore, dual inhibition does not cause bleeding risk.